aHUS digital landscape in Japan will be impacted by new entrants

10 November 2022

The entry of new treatments for atypical hemolytic uremic syndrome (aHUS) such as Swiss pharmaceutical giants Novartis (NOVN: VX) and Roche (ROG: SIX) that have strong digital experience can alter the aHUS digital landscape dynamics in Japan, says data and analytics company GlobalData.

Atulana Dey, pharma analyst at GlobalData, comments: “The incidence of the C3 variants in Japanese aHUS patients is much higher and predominant compared to other regions and races, resulting in a positive prognosis of the disease with anti-C5 therapies.”

aHUS) is an extremely rare chronic genetic disease with very limited treatment options in Japan. Soliris (eculizumab) and Ultomiris (raviluzumab LA) from Alexion, which is now is owned by AstraZeneca (LSE: AZN), are the only therapies approved. Both therapies are targeted complement C5 inhibitors. However, ravulizumab LA is the first-in-class long-acting complement C5 inhibitor that was approved in September 2020.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK